Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document C2005/304/07

Prior notification of a concentration (Case COMP/M.4007 — Reckitt Benckiser/Boots Healthcare International) Text with EEA relevance

OJ C 304, 1.12.2005, p. 21–21 (ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, NL, PL, PT, SK, SL, FI, SV)

Date of document:
01/12/2005; Date of publication
Author:
European Commission
Form:
Announcements

1.12.2005   

EN

Official Journal of the European Union

C 304/21

Prior notification of a concentration

(Case COMP/M.4007 — Reckitt Benckiser/Boots Healthcare International)

(2005/C 304/07)

(Text with EEA relevance)

1.

On 25 November 2005 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Reckitt Benckiser plc (‘Reckitt Benckiser’, United Kingdom) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Boots Healthcare International (‘BHI’, United Kingdom) by way of purchase of shares and assets.

2.

The business activities of the undertakings concerned are:

—

for Reckitt Benckiser: manufacture and sale of household products as well as health, personal care and food products;

—

for BHI: manufacture and sale mainly of over-the-counter pharmaceuticals.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4007 — Reckitt Benckiser/Boots Healthcare International, to the following address:

European Commission

Competition DG

Merger Registry

J-70

BE-1049 Brussels

(1)  OJ L 24, 29.1.2004, p. 1.

Top